Dose-dependent effect of radiation on angiogenic and angiostatic CXC chemokine expression in human endothelial cells

Cytokine

Volumn 48, Issue 3, 2009, Pages 295-302

  Chang, Christopher C ^a   Lerman, Oren Z ^a   Thanik, Vishal D ^a   Scharf, Carrie L ^a   Greives, Matthew R ^a   Schneider, Robert J ^a   Formenti, Sylvia C ^a   Saadeh, Pierre B ^a   Warren, Stephen M ^a   Levine, Jamie P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; CXC chemokine; Endothelial cells; Ionizing radiation

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 8;

ANGIOGENESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; STIMULUS; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INDUCING AGENTS; ANGIOSTATIC PROTEINS; APOPTOSIS; CELL LINE; CELL MOVEMENT; CHEMOKINES, CXC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; RECEPTORS, CXCR4; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 70350008256     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.08.007     Document Type: Article

References (39)

1. Strieter R.M., Polverini P.J., Kunkel S.L., Arenberg D.A., Burdick M.D., Kasper J., et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270 (1995) 27348-27357
2. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
3. Faria D.T., Nickoloff B.J., Poverini P.J., Kunkel S., Burdick M., and Strieter R.M. Chemokine and inflammatory cytokine changes during chronic wound healing. Wound Repair Regen 5 (1997) 310-322
4. Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 338 (1998) 436-445
5. Balkwill F. The molecular and cellular biology of the chemokines. J Viral Hepat 5 (1998) 1-14
6. Strieter R.M., Belperio J.A., Phillips R.J., and Keane M.P. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14 (2004) 195-200
7. Bernardini G., Ribatti D., Spinetti G., Morbidelli L., Ziche M., Santoni A., et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273 (2003) 83-101
8. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., and Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 42 (2006) 768-778
9. Strieter R.M., Gomperts B.N., and Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest 117 (2007) 549-556
10. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
11. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182 (1995) 155-162
12. Fujimori A., Okayasu R., Ishihara H., Yoshida S., Eguchi-Kasai K., Nojima K., et al. Extremely low dose ionizing radiation up-regulates CXC chemokines in normal human fibroblasts. Cancer Res 65 (2005) 10159-10163
13. Heissig B., Rafii S., Akiyama H., Ohki Y., Sato Y., Rafael T., et al. Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202 (2005) 739-750
14. Rafii S., and Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 9 (2003) 702-712
15. Frangogiannis N.G. The role of the chemokines in myocardial ischemia and reperfusion. Curr Vasc Pharmacol 2 (2004) 163-174
16. Frangogiannis N.G. Chemokines in ischemia and reperfusion. Thromb Haemost 97 (2007) 738-747
17. Frangogiannis N.G., and Entman M.L. Chemokines in myocardial ischemia. Trends Cardiovasc Med 15 (2005) 163-169
18. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
19. Ceradini D.J., and Gurtner G.C. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 15 (2005) 57-63
20. Tarasova N.I., Stauber R.H., and Michejda C.J. Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4. J Biol Chem 273 (1998) 15883-15886
21. Murdoch C., Monk P.N., and Finn A. Cxc chemokine receptor expression on human endothelial cells. Cytokine 11 (1999) 704-712
22. Gupta S.K., Lysko P.G., Pillarisetti K., Ohlstein E., and Stadel J.M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. J Biol Chem 273 (1998) 4282-4287
23. Petzelbauer P., Watson C.A., Pfau S.E., and Pober J.S. IL-8 and angiogenesis: evidence that human endothelial cells lack receptors and do not respond to IL-8 in vitro. Cytokine 7 (1995) 267-272
24. Schonbeck U., Brandt E., Petersen F., Flad H.D., and Loppnow H. IL-8 specifically binds to endothelial but not to smooth muscle cells. J Immunol 154 (1995) 2375-2383
25. Nor J.E., Christensen J., Mooney D.J., and Polverini P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154 (1999) 375-384
26. Rodemann H.P., and Blaese M.A. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 17 (2007) 81-88
27. Tan J., Geng L., Yazlovitskaya E.M., and Hallahan D.E. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res 66 (2006) 2320-2327
28. Toulany M., Kasten-Pisula U., Brammer I., Wang S., Chen J., Dittmann K., et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 12 (2006) 4119-4126
29. Kufe D., and Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2 (2003) 326-329
30. Ning S., Laird D., Cherrington J.M., and Knox S.J. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 157 (2002) 45-51
31. Geng L., Donnelly E., McMahon G., Lin P.C., Sierra-Rivera E., Oshinka H., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61 (2001) 2413-2419
32. Gorski D.H., Beckett M.A., Jaskowiak N.T., Calvin D.P., Mauceri H.J., Salloum R.M., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59 (1999) 3374-3378
33. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 85 (2001) 2010-2016
34. Kozin S.V., Boucher Y., Hicklin D.J., Bohlen P., Jain R.K., and Suit H.D. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 (2001) 39-44
35. Lee C.G., Heijn M., di Tomaso E., Griffon-Etienne G., Ancukiewicz M., Koike C., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60 (2000) 5565-5570
36. Lund E.L., Bastholm L., and Kristjansen P.E. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiform xenografts. Clin Cancer Res 6 (2000) 971-978
37. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 (2006) 769-777
38. Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 Suppl. 1 (2004) 43-49
39. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat Biotechnol 23 (2005) 1147-1157